SLU-PP-332
Energy · Energy, Weight Loss, Longevity
SLU-PP-332 is a synthetic agonist of the estrogen-related receptors (ERR-alpha/beta/gamma), a family of proteins that regulate mitochondrial function and energy metabolism. In mice it behaves as an exercise mimetic, increasing endurance, fat oxidation, and metabolic rate without training. It is an entirely preclinical research compound with no human studies and no validated human dose.
Research use only. Not for human consumption and not medical advice. Dosing figures are summarized from public sources and community reports, not clinical guidance.
Overview
SLU-PP-332 is a synthetic small molecule that activates the estrogen-related receptors (ERR-alpha, ERR-beta and ERR-gamma), with the strongest activity at ERR-alpha. These receptors control mitochondrial biogenesis and how cells produce and spend energy. Because it switches on some of the same pathways as exercise, it has been described as an exercise mimetic.
Evidence Quality
The evidence base is entirely preclinical. Every published dose is a mouse dose delivered by injection, and there are no human trials, no pharmacokinetic data, and no established safety margins. This places SLU-PP-332 among the least-validated compounds in community use and well below anything with clinical support.
What the Research Shows
A 2023 study in ACS Chemical Biology reported that SLU-PP-332 triggered an ERR-alpha-dependent aerobic exercise response and improved running endurance in mice. A companion paper found it alleviated features of metabolic syndrome, reducing fat mass and improving metabolic markers. Separate work showed ERR agonism reversed mitochondrial dysfunction in the aging kidney. All of these findings are in animals.
Dosage Notes
There is no validated human dose. Community subcutaneous protocols are anecdotal and typically fall somewhere between a few hundred micrograms and roughly one milligram per day, loosely mirroring the dosing used in mice. These numbers are estimates built on animal data and carry no safety assurance.
Who Should Be Cautious
Given the complete absence of human data, caution applies to everyone. ERRs are strongly expressed in the heart, so anyone with cardiovascular concerns has particular reason to avoid it. It should not be used by people who are pregnant or breastfeeding, and it is not appropriate as a self-administered supplement.
Availability
SLU-PP-332 is sold as a research chemical in lyophilized form, commonly in 1 mg and 5 mg vials, and is reconstituted with bacteriostatic water for subcutaneous injection in community use. It is not FDA approved, not a supplement, and not a prescription medication, and is labeled strictly for laboratory research.
Bottom Line
SLU-PP-332 is one of the more scientifically intriguing exercise-mimetic candidates, but it is strictly a mouse-stage compound. There is no human evidence that it is safe or effective, and any use is genuinely experimental.
Reported effects
- Endurance boost: In mice, SLU-PP-332 increased running capacity and shifted muscle toward fatigue-resistant oxidative fibers.
- Increased fat burning: The compound raised energy expenditure and reduced fat mass in rodent models of metabolic syndrome.
- Mitochondrial support: ERR activation improved mitochondrial function, including in studies of the aging kidney.
Reported side effects
- Unknown human safety: Because SLU-PP-332 has never been tested in people, its side-effect profile in humans is genuinely unknown.
- Injection-site reactions: As with any subcutaneous research injectable, users report redness, irritation, or bruising at the site.
- Cardiac and hormonal uncertainty: ERRs are highly active in the heart and other tissues, so off-target effects are a theoretical concern that is unstudied in humans.
Community reviews
Share your own experience with SLU-PP-332. Reviews are moderated and help others avoid scams.
Loading reviews…